Egalet’s management team has extensive experience in the pharmaceutical and biotechnology industry and has a track record of successfully developing and commercializing products.
President and Chief Executive Officer
Mr. Radie is president, chief executive officer and a member of Egalet’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005 Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a public commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.
Mark Strobeck, Ph.D.
Executive Vice President and Chief Operating Officer
Dr. Strobeck is executive vice president and chief operating officer, a position he’s held since October 2015. He joined Egalet in February 2014 as chief business officer (CBO). Previously Dr. Strobeck was president and chief executive officer of Corridor Pharmaceuticals which he successfully sold to AstraZeneca and chief business officer of Topaz Pharmaceuticals which he sold to Sanofi Pasteur. Dr. Strobeck was chief business officer at Trevena Inc., and vice president of business development at GlaxoSmithKline. Before working at these healthcare companies, Dr. Strobeck was a venture capitalist at SR One Ltd., the wholly owned venture capital arm of GSK and Euclid SR Partners.
Dr. Strobeck earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati, completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania and received his bachelor’s degree from St. Lawrence University.
Barbara A. Carlin
Chief Accounting Officer
Ms. Carlin is our chief accounting officer a position she’s held since January 2016. She joined Egalet in January 2014 as vice president, finance and administration. For more than 15 years Ms. Carlin has provided financial and operational leadership to public and privately held companies with a focus on the emerging growth life sciences community. During that time, she worked at several biotechnology and specialty pharmaceutical companies including: Topaz Pharmaceuticals Inc., moksha8 Pharmaceuticals, Inc., Genaera Corporation and Vicuron Pharmaceuticals, Inc. She also served in various roles in finance and accounting at publically held companies in the professional services and publishing space. Ms. Carlin started her career in accounting at Deloitte and Touche LLP. She earned her bachelor’s degree in accounting from St. Joseph’s University and is a certified public accountant in the Commonwealth of Pennsylvania.
E. Blair Clark-Schoeb
Senior Vice President, Communications
Ms. Clark-Schoeb, senior vice president, communications, leads our investor relations, public relations, advocacy relations and government affairs work. She has two decades of experience helping healthcare companies develop unique and effective communications programs. Prior to joining Egalet in February 2015, Ms. Clark-Schoeb led her own consulting business, working with pharmaceutical and biotechnology companies such as Sanofi, Syndax, Horizon Pharmaceuticals and Topaz Pharmaceuticals. Prior to that she was senior associate at W2O, director of investor relations at Burns McClellan, director of corporate finance at The Medicines Company and a healthcare investment banker at Donaldson, Lufkin and Jenrette. Ms. Clark-Schoeb received her bachelor’s degree from Harvard University.
Karsten Lindhardt, M.Sc., Ph.D.
Chief Scientific Officer
Dr. Lindhardt is chief scientific officer, a position held since October 2017. He previously served as senior vice president of research and development from December 2013 to October 2017, as vice president, research and development from April 2011 to December 2013 and senior director of portfolio management and alliance manager from March 2010 to April 2011. From August 2008 to March 2010, Dr. Lindhardt served as the director of portfolio management for our predecessor Egalet A/S, and as a project manager from March 2008 to August 2008. Before joining Egalet A/S, Dr. Lindhardt served in management positions for Curalogic A/S and OSI Pharmaceuticals, and as a clinical pharmacologist for Ferring Pharmaceuticals and Novo Nordisk A/S. Dr. Lindhardt received an M.Sci. in Pharmaceutics, a Ph.D. in pharmaceutical development and pharmacology, each from the Royal Danish School of Pharmacy, and a Diploma of Business Excellence (DBE) from Columbia University and Copenhagen Business School.
Chief Commercial Officer
Mr. Shea serves as Egalet’s chief commercial officer and has held this position since he joined the company in September 2016. Mr. Shea has over two decades of sales, marketing, market access and commercial operations experience. He most recently served as CCO at Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company. Prior to Clarus he served as vice president of sales and marketing for the U.S. commercial operations of CSL Behring, where he oversaw strategic efforts for sales, marketing and managed care business. Before that he was as senior vice president of sales and marketing for the U.S. pharmaceutical operations at Astellas Pharmaceuticals, and held senior sales and marketing roles at Ligand Pharmaceuticals and Boehringer Ingelheim. Mr. Shea received his bachelor’s degree in Psychology from Alfred University.